Comparative Evaluation of the Apoptosis Effect of a Benzimidazole-Based Compound and Cisplatin in DLD-1 and MDA-MB-231 Cell Lines
DOI:
https://doi.org/10.5281/zenodo.16733438Anahtar Kelimeler:
Apoptosis, Benzimidazole, Breast cancer cisplatin, Colorectal cancerÖzet
Benzimidazole derivatives have shown promising anticancer potential due to their ability to interact with tubulin and other critical cellular targets. This study investigates the apoptotic effects of a known benzimidazole derivative, SN-6, in comparison with cisplatin in two human cancer cell lines: DLD-1 (colorectal adenocarcinoma) and MDA-MB-231 (triple-negative breast cancer). Using Annexin V, SN-6 was found to induce significantly higher levels of early and late apoptosis in both cell lines than cisplatin after 48 hours of treatment. These findings highlight the potent pro-apoptotic activity of SN-6, suggesting its potential as a promising lead compound for anticancer therapy targeting apoptosis pathways in colorectal and triple-negative breast cancers.
Referanslar
Akkoc, S., Sahin, D., Muhammed, M.T., Yıldız, M., Ilhan, I.O., 2024. Synthesis, characterization, antiproliferative activity, docking, and molecular dynamics simulation of new 1,3-dihydro-2H-benzimidazol-2-one derivatives. Journal of Biomolecular Structure & Dynamics, 42(21): 11495–11507.
Bilici, E., Akkoç, S., 2025. In vitro cytotoxicity in A549, Hepg2, MCF-7, and DLD-1 cancer cell lines and ADME/ toxin analysis of a benzimidazole derivative. Journal of King Saud University - Science, 2: 1-6.
Cho N, Kasai S, Yamashita T. 2006. Preparation of 3-benzylpyrolidin-2-one and N-benzylimid azolidin-2-one derivatives as prophylactic/therapeutic agents for diabetes. World Intellectual Property Organization, WO2006104280 A1 2006-10-05.
Galluzzi, L., Senovilla, L., Vitale, I., Michels, S., Martins, I., Kepp, O., Castedo, M., Kroemer, G., 2012. Molecular mechanisms of cisplatin resistance. Oncogene, 31(15): 1869–1886.
Hasanpourghadi, M., Karthikeyan, C., Pandurangan, A. K., Looi, C.Y., Trivedi, P., Kobayashi, K., Tanaka, K., Wong, W.F., Mustafa, M.R., 2016. Targeting of tubulin polymerization and induction of mitotic blockage by Methyl 2-(5-fluoro-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylate (MBIC) in human cervical cancer HeLa cell. Journal of Experimental & Clinical Cancer Research, 35, 58.
Kavya, G., Sivan, A., 2022. Exploring the versatility of benzimidazole scaffolds as medicinal agents: A brief update. In IntechOpen.
Kim, J.S., Gatto, B., Yu, C., Liu, A., Liu, L. F., LaVoie, E.J., 1996. Substituted 2,5'-Bi-1H-benzimidazoles: Topoisomerase I inhibition and cytotoxicity. Journal of Medicinal Chemistry, 39(4): 992–998.
Laxmikeshav, K., Himaja, A., Shankaraiah, N., 2022. Exploration of benzimidazoles as potential microtubule modulators: An insight in the synthetic and therapeutic evolution. Journal of Molecular Structure, 1253: 132251.
Lee, Y.T., Tan, Y.J., Oon, C.E., 2023. Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine. Acta Pharmaceutica Sinica B, 13(2): 478–497.
Liu, P., Kumar, I.S., Brown, S., Kannappan, V., Tawari, P.E., Tang, J.Z., Jiang, W., Armesilla, A.L., Darling, J.L., Wang, W., 2013. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. British Journal of Cancer, 109(7): 1876–1885.
Longley, D.B., Johnston, P.G., 2005. Molecular mechanisms of drug resistance. The Journal of Pathology, 205(2): 275–292.
Monga, J., Ghosh, N.S., Rani, I., Singh, R., Deswal, G., Dhingra, A.K., Grewal, A.S., 2024. Unlocking the pharmacological potential of benzimidazole derivatives: A pathway to drug development. Current Topics in Medicinal Chemistry, 24(5): 437–485.
Neve, R.M., Chin, K., Fridlyand, J., Yeh, J., Kuo, F., Davies, R.W., Barretina, M., Clark, M.J., Mills, G.B., Jané-Valbuena, A., Klijn, C., Goldfine, J., Roberts, R.B., Poling, S., Carter, H., Lee, W.L., Hu, L.M., Taylor, B.S., Brown, P.O., Gray, J.W., 2006. A collection of breast cancer cell lines for the study of functionally defined cancer subtypes. Cancer Cell, 10(6): 515–527.
Piotrowska, H., Kucinska, M., Murias, M., 2013. Expression of CYP1A1, CYP1B1 and MnSOD in a panel of human cancer cell lines. Molecular and Cellular Biochemistry, 383(1–2): 95–102.
Rosenberg, B., VanCamp, L., Trosko, J.E., Mansour, V.H., 1969. Platinum compounds: A new class of potent antitumour agents. Nature, 222(5191): 385–386.
Sánchez-Díez, M., Alegría-Aravena, N., López-Montes, M., Quiroz-Troncoso, J., González-Martos, R., Menéndez-Rey, A., Sánchez-Sánchez, J.L., Pastor, J.M., Ramírez-Castillejo, C., 2022. Implication of different tumor biomarkers in drug resistance and invasiveness in primary and metastatic colorectal cancer cell lines. Biomedicines, 10(5): 1083.
Sarhan, A.A., Al-Dhfyan, A., Al-Mozaini, M.A., Adra, C.N., Aboul-Fadl, T., 2010. Cell cycle disruption and apoptotic activity of 3-aminothiazolo[3,2-a] benzimidazole-2-carbonitrile and its homologues. European Journal of Medicinal Chemistry, 45(6): 2689–2694.
Siddik, Z.H., 2003. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene, 22(47): 7265–7279.
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, M., Jemal, A., Bray, F. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3): 209–249.
Zhang, Y., Wu, J., Ye, M., Wang, B., Sheng, J., Shi, B., Chen, H., 2018. ETS1 is associated with cisplatin resistance through IKKα/NF-κB pathway in cell line MDA-MB-231. Cancer Cell International, 18: 86.
İndir
Yayınlanmış
Nasıl Atıf Yapılır
Sayı
Bölüm
Lisans
Telif Hakkı (c) 2025 Euroasia Matematik, Mühendislik, Doğa ve Tıp Bilimleri Dergisi Medical Sciences
Bu çalışma Creative Commons Attribution-NonCommercial 4.0 International License ile lisanslanmıştır.
Dergimizde yayımlanan makaleler, 